Sahu Chinmoy, Singh Sweta, Pathak Ashutosh, Patel Sangram Singh, Ghoshal Ujjala, Singh Uday Shanker, Hashim Zia
Department of Microbiology, SGPGIMS, Lucknow, Uttar Pradesh, India.
Department of Microbiology, ASMC, Mirzapur, Uttar Pradesh, India.
J Family Med Prim Care. 2022 Oct;11(10):6255-6259. doi: 10.4103/jfmpc.jfmpc_548_22. Epub 2022 Oct 31.
Coronavirus disease 2019 (COVID-19) is purely a viral illness which is not affected by the usage of antibiotics, but the risk of development of secondary bacterial infections during the course of respiratory illness or hospitalisation has led to a surge of antibiotic use. Anti-microbial resistance has taken an upward trend to some of the commonly used or over-used antibiotics. The present study was planned to focus on the trends of resistance rates noticed for the common antibiotics, namely, doxycycline, azithromycin, and so on, before and after the advent of this pandemic.
The study was conducted at a tertiary care hospital of North India with 2000 samples, 1000 samples between March 2019 and March 2020 before the COVID pandemic and 1000 samples between April 2020 and April 2021 after the advent of the pandemic. Identification and zones for doxycycline and erythromycin were interpreted as per Clinical and Laboratory Standards Institute guidelines.
Among the various samples, pus/aspirated fluids were in majority (47%), followed by blood (29%), respiratory specimens (18%), and urine (6%). On stratifying the various pathogens associated with the treatment of doxycycline and erythromycin, species were the predominant ones in almost 82% of the cases, followed by (12%) and (6%) species. For doxycycline, the overall sensitivity was noted to be 46% in the year 2019-20 and 31% in the year 2020-21, whereas for erythromycin, the sensitivity was seen as 39% in 2019-20 and dropped down to 26% in 2020-21.
The authors noted a dip in the overall sensitivity towards doxycycline and azithromycin. This finding clearly indicates the increasing rates of antibiotic resistance in a developing country such as India during these COVID times. A proper anti-microbial stewardship programme during these times will help to de-escalate the increasing resistance rates and will prove to be of great help to the primary care physicians.
2019冠状病毒病(COVID-19)纯粹是一种病毒性疾病,不受抗生素使用的影响,但在呼吸道疾病或住院期间发生继发性细菌感染的风险导致了抗生素使用的激增。对一些常用或过度使用的抗生素而言,抗菌耐药性呈上升趋势。本研究旨在关注在这场大流行出现之前和之后,常见抗生素(如多西环素、阿奇霉素等)耐药率的变化趋势。
该研究在印度北部一家三级护理医院进行,共采集2000份样本,其中1000份样本采集于2019年3月至2020年3月,即COVID大流行之前;另外1000份样本采集于2020年4月至2021年4月,即大流行出现之后。根据临床和实验室标准协会的指南对多西环素和红霉素的鉴定及抑菌圈进行解读。
在各类样本中,脓液/抽吸液占多数(47%),其次是血液(29%)、呼吸道标本(18%)和尿液(6%)。在对与多西环素和红霉素治疗相关的各种病原体进行分层时,在几乎82%的病例中,[具体菌种1]是主要菌种,其次是[具体菌种2](12%)和[具体菌种三](6%)。对于多西环素,2019 - 20年的总体敏感性为46%,2020 - 21年为31%;而对于红霉素,2019 - 20年的敏感性为39%,2020 - 21年降至26%。
作者注意到对多西环素和阿奇霉素的总体敏感性有所下降。这一发现清楚地表明,在印度这样的发展中国家处于这些COVID时期,抗生素耐药率在上升。在这些时期实施适当的抗菌管理计划将有助于降低不断上升的耐药率,并将对初级保健医生有很大帮助。